Regeneron Gains 1.15% to $768.64 Following Conference Updates
Cowen & Co retained its Buy rating for Regeneron after the company presented new drug development updates at the TD Cowen 46th Annual Health Care Conference. The stock rose 1.15% to $768.64 on March 9, trading between $753.74 and $770.25 as market cap reached $79.9 billion.
1. Cowen Maintains Buy Rating
Cowen & Co reiterated its Buy rating on Regeneron, valuing the stock at $764.11 and signaling confidence in the company’s mid- to long-term growth prospects based on its R&D pipeline and clinical milestones.
2. Conference Presentation Highlights
At the TD Cowen 46th Annual Health Care Conference, Regeneron showcased progress on its late-stage candidates, emphasizing advancements in eye disease treatments and oncology immunotherapies, and outlined upcoming trial readouts.
3. Stock Movement Details
Following the conference, Regeneron’s shares climbed 1.15% to $768.64, trading within a intraday range of $753.74 to $770.25 on volume of 132,758 shares, reflecting heightened investor interest in its development updates.
4. Market Position and Valuation
Regeneron’s market capitalization stands at approximately $79.9 billion, and its share price has ranged from $476.49 to $821.11 over the past year, underscoring its resilience and competitive stance in the biotechnology sector.